ORGANIZATION
    Digital Health Group Eager to Gain Full Seat at Chuikyo Table
    By Ken Yoshino September 25, 2026
    The Japan Digital Health Alliance (JaDHA) is preparing to throw its support behind proposed reforms to the Central Social Insurance Medical Council (Chuikyo), while signaling its interest in securing a full seat on the powerful…

    LATEST

    MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
    September 25, 2026
    Japan needs to go further in accepting English-language drug application dossiers in a bid to tackle drug lag and loss, the health ministry’s new top pharmaceutical affairs official says, pointing to the need to make…
    European Pharma Chairs Urge Policy Shift on Innovative Drug Investment
    September 25, 2026
    The chairs of nine European pharmaceutical companies have called on EU and national policymakers to reverse underinvestments in innovative drugs and better recognize the full value that medicines bring to patients, healthcare systems, and the…
    Japan Wholesalers’ Profit Margin Worsens to 1.04% as Costs Rise
    September 25, 2026
    Japanese pharmaceutical wholesalers saw their operating profit margin fall to 1.04% in FY2025 from 1.11% the previous year, according to a survey released on September 24 by the Federation of Japan Pharmaceutical Wholesalers Association (JPWA).The…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
    By Tatsuya Otsuka

    Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA